Kynurenic acid

製品コードS4719 バッチS471905

印刷

化学情報

Chemical Structure Synonyms Quinurenic acid, Kynurenate Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C10H7NO3
分子量 189.17 CAS No. 492-27-3
Solubility (25°C)* 体外 DMSO 10 mg/mL (52.86 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

 0.500mg/ml (2.64mM) Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

 0.250mg/ml (1.32mM) Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Kynurenic acid (Quinurenic acid, Kynurenate), a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist; It proved to be an antagonist at NMDA, kainate and AMPA receptors.
in vitro Kynurenic acid(KYNA) is neuroactive tryptophan metabolites formed along the kynurenine pathway. It is considered a non-competitive antagonist of glutamate receptors of NMDA type. KYNA, at low concentration, inhibits FGF-1 release in all cellular models and displays a major stimulatory effect on the proliferation rate of mouse microglia and human glioblastoma cells, in vitro[2].
in vivo Treatment with KYNA (30–100 mg per kg of body weight, intravenously) 4 h before the start of heat stress significantly (P<0.05) and dose-dependently decreases the survival time to new values of 152–356 min compared with normothermic rats. KYNA protects against hypotension but not hyperthermia during heatstroke. KYNA attenuates hypothalamic neuronal degeneration and apoptosis during heatstroke. Also spleen, kidney, liver, and lung apoptosis during heatstroke are decrease. KYNA up-regulates serum IL-10 levels but down-regulates serum TNF-α and ICAM-1 levels. KYNA treatment significantly prevents the occurrence of heat-induced multi-organ damage and inflammation without affecting the induced hyperthermia. Only high doses of KYNA proved to be neuroprotective in neonatal rats by reducing anoxia or hypoxia-ischemia-induced brain edema and in adult rats and gerbils given before ischemia induction. KYNA cannot cross the blood-brain barrier[3].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 N11 cells, U-343 MG cells, HUVE cells
濃度 1 μM or 10 μM
反応時間
実験の流れ

N11 cells are seeded at a density of 4×104 cells/well in 6-well cluster plates and grown in DMEM supplemented with 0.5% FBS with or without KYNA or QUIN. U-343 MG cells are seeded at a density of 4×104 cells/well in 6-well cluster plates and grown in DMEM supplemented with 10% or 3% FBS, with or without KYNA. HUVE cells at passage 3 are seeded at a density of 2×104 cells/well in 6-well cluster plates and grown in M199 supplemented with 10% FBS, 5 U/ml heparin, with or without KYNA, in the presence or absence of 20 ng/ml FGF-1 recombinant protein. Cells are fed every 2 days with fresh medium. The number of viable cells is counted after trypsinization by hemacytometer at timed intervals, in triplicates, using two separate measurements per well. A statistical comparison between growth curves at each observation point was performed by using the Student’s t-test. A p-value less than 0.05 was considered statistically significant.
動物実験 動物モデル Adult male Sprague-Dawley rats
投薬量 30-100 mg/kg
投与方法 i.v

参考

  • https://pubmed.ncbi.nlm.nih.gov/25674503/
  • https://pubmed.ncbi.nlm.nih.gov/16392031/
  • https://pubmed.ncbi.nlm.nih.gov/21293468/
  • https://pubmed.ncbi.nlm.nih.gov/6215086/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

KYNA Ameliorates Hepatic Ischemia-Reperfusion Injury by Activating the Hippo Signalling Pathway via FTO-Dependent m6A Demethylation of LATS1 [ Cell Prolif, 2025, e70048.] PubMed: 40277037
Characterization of Non-Specific Uptake and Retention Mechanisms of [177Lu]Lu-PSMA-617 in the Salivary Glands [ Pharmaceuticals (Basel), 2023, 16(5)692] PubMed: 37242475
Organ-differential responses to ethanol and kynurenic acid, a component of alcoholic beverages in gene transcription. [ Gene, 2020, 737:144434] PubMed: 32018015

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。